Treatment of hepatitis B virus infection in patients coinfected with HIV

Gastroenterology Clinics of North America

Volumn 33, Issue 3, 2004, Pages 617-627

  Benhamou, Yves ^a   Bonyhay, Luminita ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA2 INTERFERON; ANTIVIRUS AGENT; LAMIVUDINE; LOVIRIDE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DISEASE; PREVALENCE; REVIEW; SEROCONVERSION; SUPERINFECTION; VIRUS REPLICATION; VIRUS VIRULENCE;

ADENINE; ANTIVIRAL AGENTS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 8444247877     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2004.04.010     Document Type: Review

References (42)

1. Maddrey W.C. Hepatitis B: an important public health issue. Clin Lab. 47:2001;51-55
2. Rustgi V.K., Hoofnagle J.H., Gerin J.L., Gelmann E.P., Reichert C.M., Cooper J.N., et al. Hepatitis B infection in the acquired immunodeficiency syndrome. Ann Intern Med. 101:1984;795-797
3. Bodsworth N.J., Cooper D.A., Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis. 163:1991;1138-1140
4. Gilson R.J., Hawkins A.E., Beecham M.R., Ross E., Waite J., Briggs M., et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS. 11:1997;597-606
5. Taylor P.E., Stevens C.E., DeCordoba S.R., Rubinstein P. Hepatitis B virus and human immunodeficiency virus: possible interactions. Zuckerman A.J. Viral hepatitis and liver disease. 1988;198-200 Alan R Liss, New York
6. Perrillo R.P., Regenstein F.G., Roodman S.T. Chronic hepatitis B in asymptomatic homosexual men with antibody to the human immunodeficiency virus. Ann Intern Med. 105:1986;382-383
7. Rector W.G. Jr., Govindarajan S., Horsburgh C.R. Jr., Penley K.A., Cohn D.L., Judson F.N. Hepatic inflammation, hepatitis B replication, and cellular immune function in homosexual males with chronic hepatitis B and antibody to human immunodeficiency virus. Am J Gastroenterol. 83:1988;262-266
8. Colin J.F., Cazals-Hatem D., Loriot M.A., Martinot-Peignoux M., Pham B.N., Buchbinder S., et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology. 29:1999;1306-1310
9. Puoti M., Spinetti A., Ghezzi A., Donato F., Zaltron S., Putzolu V., et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr. 24:2000;211-217
10. Thio C.L., Seaberg E.C., Skolasky R. Jr., Phair J., Visscher B., Munoz A., et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 14:(360):2002;1921-1926
11. Wong D.K., Yim C., Naylor C.D., Chen E., Sherman M., Vas S., et al. Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population. Gastroenterology. 108:1995;165-171
12. MacDonald J.A., Caruso L., Karayannis P., Scully J., Harris J.R.W., Forster G.E., et al. Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV III antibodies to recombinant alfa interferon. Hepatology. 7:1987;719-723
13. Brook M.G., Karayiannis P., Thomas H.C. Which patients with chronic hepatitis B virus infection will respond to alfa-interferon therapy? A statistical analysis of predictive factors. Hepatology. 10:1989;761-763
14. Scully L.J., Lever A.M., Yap I., Pignatelli M., Thomas H.C. Identification of factors influencing response rate to antiviral therapy of chronic hepatitis B virus infection. A review of the efficacy of adenine arabinoside and lymphoblastoid interferon in the Royal Free Hospital studies. J Hepatol. 3:1986;S291-S299
15. Marcellin P., Boyer N., Colin J.F., Martinot-Peignoux M., Lefort V., Matheron S., et al. Recombinant alfa interferon for chronic hepatitis B in anti-HIV positive patients receiving zidovudine. Gut. 34:1993;S106
16. Zylberberg H., Jiang J., Pialoux G., Driss F., Carnot F., Dubois F., et al. Alfa-interferon for chronic active hepatitis B in human immunodeficiency virus-infected patients. Gastroenterol Clin Biol. 20:1996;968-971
17. Benhamou Y., Katlama C., Lunel F., Coutellier A., Dohin E., Hamm N., et al. The effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med. 125:1996;705-712
18. Dore G.J., Cooper D.A., Barrett C., Goh L.E., Thakrar B., Atkins M. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis. 180:1999;607-613
19. CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet. 349:1997;1413-1421
20. Schuurman R., Nijhuis M., van Leeuwen R., Schipper P., de Jong D., Collis P., et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 171:1995;1411-1419
21. Back N.K., Nijhuis M., Keulen W., Boucher C.A., Oude Essink B.O., van Kuilenburg A.B., et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 15:1996;4040-4049
22. Miller V., Stark T., Loeliger A.E., Lange J.M. The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response. HIV Med. 3:2002;135-145
23. Bartholomew M.M., Jansen R.W., Lennox J.J., Jeffers J., Reddy K.R., Johnson L.C., et al. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet. 349:1997;20-22
24. Ling R., Mutimer D., Ahmed M., Boxall E.H., Elias E., Dusheiko G.M., et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology. 24:1996;3711-3713
25. Benhamou Y., Bochet M., Thibault V., Di Martino V., Caumes E., Bricaire F., et al. Long-term incidence of hepatitis B virus resistance to lamivudine in HIV-infected patients. Hepatology. 30:1999;1302-1306
26. Thibault V., Benhamou Y., Seguret C., Bochet M., Katlama C., Bricaire F., et al. Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus. J Clin Microbiol. 37:1999;3013-3016
27. Pillay D., Cane P.A., Ratcliffe D., Atkins M., Cooper D. Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in coinfected individuals: an analysis of the CAESAR study. CAESAR Coordinating Committee. AIDS. 14:2000;1111-1116
28. Bruno R., Sacchi P., Malfitano A., Filice G. YMDD-mutant HBV strain as a cause of liver failure in an HIV-infected patient. Gastroenterology. 121:2001;1027-1028
29. Bonacini M., Kurz A., Locarnini S., Ayres A., Gibbs C. Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV. Gastroenterology. 122:2002;244-245
30. Bessesen M., Ives D., Condreay L., Sherman K.E. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis. 28:1999;1032-1035
31. Xiong X., Flores C., Fuller M., Mendel D., Mulato A., Moon K., et al. In vitro characterization of the antihuman cytomegalovirus activity of PMEA (adefovir). Antiviral Res. 36:1997;131-137
32. Xiong X., Flores C., Yang H., Toole J., Gibbs C. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology. 28:1998;1669-1673
33. Marcellin P., Chang T.T., Lim S.G., Tong M., Sievert W., Shiffman M., et al. Adefovir dipivoxil for the treatment of hepatitis B antigen-positive chronic hepatitis B. N Engl J Med. 348:2003;808-816
34. Hadziyannis S.J., Tassopoulos N.C., Heathcote E., Chang T.T., Kitis G., Rizzetto T., et al. Adefovir dipivoxil for the treatment of hepatitis B antigen-negative chronic hepatitis B. N Engl J Med. 348:2003;800-807
35. Benhamou Y., Bochet M., Thibault V., Calvez V., Fievet M.H., Vig P., et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus. Lancet. 358:(Supp 1):2001;718-723
36. Benhamou Y., Bochet M., Thibault V., Calvez V., Fievet M.H., Vig P., et al. Safety and efficacy of long-term adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in HIV infected patients [abstract]. J Hepatol. 36:(Supp 1):2002;138
37. Peters M., Hann H.W., Martin P., Heathcote E., Buggisch P., Moorat A.E., et al. Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses LAM-resistant hepatitis B virus (HBV) replication: 16 week interim analysis [abstract]. J Hepatol. 36:(Suppl 1):2002;6
38. Ying C., De Clercq E., Nicholson W., Furman P., Neyts J. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir, and lobucavir. J Viral Hepat. 7:2000;161-165
39. Benhamou Y., Bochet M., Tubiana R., Thibault V., Suffisseau L., Sullivan M., et al. Tenofovir disoproxil fumarate suppresses lamivudine resistant HBV replication in patients co-infected with HIV/HBV. N Engl J Med. 348:2003;177-178
40. Dore G.J., Cooper D.A., Pozniac A.L., DeJesus E., Zhong L., Miller M.D., et al. Efficacy of tenofovir disoproxil fomarate in anti-retroviral therapy naive and experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis. 189:2004;1185-1192
41. Nelson M., Portsmouth S., Stebbing J., Atkins M., Barr A., Matthews G., et al. An open-label study of tenofovir in HIV-1 and Hepatitis B virus coinfected individuals. AIDS. 17:2003;F7-F10
42. Ristig M.B., Crippin J., Aberg J.A., Powderly W.G., Lisker-Melman M., Kessels L., et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alfa and lamivudine therapy have failed. J Infect Dis. 186:2002;1844-1847